Literature DB >> 24777450

RAF1 mutations in childhood-onset dilated cardiomyopathy.

Rumiko Matsuoka1,2, Kumarasamy Thangaraj3, Bruce D Gelb4,5,6, Perundurai S Dhandapany4,5,6, Md Abdur Razzaque7, Uthiralingam Muthusami8, Sreejith Kunnoth8, Jonathan J Edwards6, Sonia Mulero-Navarro6, Ilan Riess6, Sherly Pardo9, Jipo Sheng10, Deepa Selvi Rani3, Bindhu Rani11, Periyasamy Govindaraj12, Elisabetta Flex13, Tomohiro Yokota1, Michiko Furutani1,2, Tsutomu Nishizawa1, Toshio Nakanishi1,2, Jeffrey Robbins7, Giuseppe Limongelli14, Roger J Hajjar10, Djamel Lebeche10, Ajay Bahl11, Madhu Khullar11, Andiappan Rathinavel15, Kirsten C Sadler16, Marco Tartaglia13.   

Abstract

Dilated cardiomyopathy (DCM) is a highly heterogeneous trait with sarcomeric gene mutations predominating. The cause of a substantial percentage of DCMs remains unknown, and no gene-specific therapy is available. On the basis of resequencing of 513 DCM cases and 1,150 matched controls from various cohorts of distinct ancestry, we discovered rare, functional RAF1 mutations in 3 of the cohorts (South Indian, North Indian and Japanese). The prevalence of RAF1 mutations was ~9% in childhood-onset DCM cases in these three cohorts. Biochemical studies showed that DCM-associated RAF1 mutants had altered kinase activity, resulting in largely unaltered ERK activation but in AKT that was hyperactivated in a BRAF-dependent manner. Constitutive expression of these mutants in zebrafish embryos resulted in a heart failure phenotype with AKT hyperactivation that was rescued by treatment with rapamycin. These findings provide new mechanistic insights and potential therapeutic targets for RAF1-associated DCM and further expand the clinical spectrum of RAF1-related human disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24777450      PMCID: PMC4049514          DOI: 10.1038/ng.2963

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  18 in total

Review 1.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy.

Authors:  Ray E Hershberger; Jill D Siegfried
Journal:  J Am Coll Cardiol       Date:  2011-04-19       Impact factor: 24.094

2.  The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs.

Authors:  Kristen M Kwan; Esther Fujimoto; Clemens Grabher; Benjamin D Mangum; Melissa E Hardy; Douglas S Campbell; John M Parant; H Joseph Yost; John P Kanki; Chi-Bin Chien
Journal:  Dev Dyn       Date:  2007-11       Impact factor: 3.780

3.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

4.  Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome.

Authors:  Angela E Lin; Mark E Alexander; Steven D Colan; Bronwyn Kerr; Katherine A Rauen; Jacqueline Noonan; Jeanne Baffa; Elizabeth Hopkins; Katia Sol-Church; Giuseppe Limongelli; Maria Christina Digilio; Bruno Marino; A Micheil Innes; Yoko Aoki; Michael Silberbach; Marie-Ange Delrue; Susan M White; Robert M Hamilton; William O'Connor; Paul D Grossfeld; Leslie B Smoot; Robert F Padera; Karen W Gripp
Journal:  Am J Med Genet A       Date:  2011-02-22       Impact factor: 2.802

5.  Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.

Authors:  Xue Wu; Jiani Yin; Jeremy Simpson; Kyoung-Han Kim; Shengqing Gu; Jenny H Hong; Peter Bayliss; Peter H Backx; Benjamin G Neel; Toshiyuki Araki
Journal:  Mol Cell Biol       Date:  2012-07-23       Impact factor: 4.272

Review 6.  The genetics of dilated cardiomyopathy.

Authors:  Lisa Dellefave; Elizabeth M McNally
Journal:  Curr Opin Cardiol       Date:  2010-05       Impact factor: 2.161

7.  Germline gain-of-function mutations in RAF1 cause Noonan syndrome.

Authors:  M Abdur Razzaque; Tsutomu Nishizawa; Yuta Komoike; Hisato Yagi; Michiko Furutani; Ryunosuke Amo; Mitsuhiro Kamisago; Kazuo Momma; Hiroshi Katayama; Masao Nakagawa; Yuko Fujiwara; Masaki Matsushima; Katsumi Mizuno; Mika Tokuyama; Hamao Hirota; Jun Muneuchi; Toru Higashinakagawa; Rumiko Matsuoka
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

Review 8.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Opin Genet Dev       Date:  2009-05-19       Impact factor: 5.578

9.  RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.

Authors:  Bruce D Gelb; Marco Tartaglia
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

10.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.

Authors:  Bhaswati Pandit; Anna Sarkozy; Len A Pennacchio; Claudio Carta; Kimihiko Oishi; Simone Martinelli; Edgar A Pogna; Wendy Schackwitz; Anna Ustaszewska; Andrew Landstrom; J Martijn Bos; Steve R Ommen; Giorgia Esposito; Francesca Lepri; Christian Faul; Peter Mundel; Juan P López Siguero; Romano Tenconi; Angelo Selicorni; Cesare Rossi; Laura Mazzanti; Isabella Torrente; Bruno Marino; Maria C Digilio; Giuseppe Zampino; Michael J Ackerman; Bruno Dallapiccola; Marco Tartaglia; Bruce D Gelb
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

View more
  27 in total

1.  Pathway-based variant enrichment analysis on the example of dilated cardiomyopathy.

Authors:  Christina Backes; Benjamin Meder; Alan Lai; Monika Stoll; Frank Rühle; Hugo A Katus; Andreas Keller
Journal:  Hum Genet       Date:  2015-11-07       Impact factor: 4.132

2.  SOS1 Gain-of-Function Variants in Dilated Cardiomyopathy.

Authors:  Jason R Cowan; Lorien Salyer; Nathan T Wright; Daniel D Kinnamon; Pedro Amaya; Elizabeth Jordan; Michael J Bamshad; Deborah A Nickerson; Ray E Hershberger
Journal:  Circ Genom Precis Med       Date:  2020-06-30

3.  Cardiac Gab1 deletion leads to dilated cardiomyopathy associated with mitochondrial damage and cardiomyocyte apoptosis.

Authors:  J Zhao; M Yin; H Deng; F Q Jin; S Xu; Y Lu; M A Mastrangelo; H Luo; Z G Jin
Journal:  Cell Death Differ       Date:  2015-10-30       Impact factor: 15.828

4.  GENETIC CAUSES OF DILATED CARDIOMYOPATHY.

Authors:  Luisa Mestroni; Francesca Brun; Anita Spezzacatene; Gianfranco Sinagra; Matthew Rg Taylor
Journal:  Prog Pediatr Cardiol       Date:  2014-12

5.  NOTCH4 is a possible novel susceptibility gene for dilated cardiomyopathy in the Chinese population: A case-control study.

Authors:  Xiaoqing Shi; Yang Zhang; Bingjie Li; Mengle Peng; Yingying Yuan; Ximing Wang; Xinqiang Li; Dongze Yu; Yongzhe Li; Dongchun Qin
Journal:  J Clin Lab Anal       Date:  2018-03-26       Impact factor: 2.352

6.  De novo RRAGC mutation activates mTORC1 signaling in syndromic fetal dilated cardiomyopathy.

Authors:  Michael T Zimmermann; Maengjo Kim; Pamela A Long; Jared M Evans; Xiaolei Xu; Timothy M Olson
Journal:  Hum Genet       Date:  2016-05-27       Impact factor: 4.132

Review 7.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

Review 8.  Animal and in silico models for the study of sarcomeric cardiomyopathies.

Authors:  Dirk J Duncker; Jeroen Bakkers; Bianca J Brundel; Jeff Robbins; Jil C Tardiff; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-18       Impact factor: 10.787

9.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

10.  NGS testing for cardiomyopathy: Utility of adding RASopathy-associated genes.

Authors:  Ozge Ceyhan-Birsoy; Maya M Miatkowski; Elizabeth Hynes; Birgit H Funke; Heather Mason-Suares
Journal:  Hum Mutat       Date:  2018-05-16       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.